| Name | Title | Contact Details |
|---|---|---|
Bill Kampine |
Co-founder, Senior Vice President and Chief Innovation Officer | Profile |
Erik Nicholson |
Senior Vice President of Technology and Chief Information Officer | Profile |
David McHenry |
Executive Director of Information Security | Profile |
St Joseph Nursing Home is a Utica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Montefiore St. Luke`s Cornwall (MSLC) is a not-for-profit community hospital with campuses in Newburgh and Cornwall, NY. The hospital is dedicated to serving the health care needs of the Hudson Valley and has achieved excellence in the delivery of compassionate and comprehensive health care services. The Joint Commission noted MSLC for excellence in Key Quality Measures in the management of Heart Attack, Heart Failure, Stroke and Surgical Care. MSLC is also recognized as an industry leader in using information technology to improve patient care, by winning the Most Wired Award for the fourth year in a row. In January 2018, MSLC officially became part of the Montefiore Health System to strengthen the delivery of health care locally and enhance access to exceptional specialty care for Hudson Valley residents.
Breckinridge Memorial Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Hardinsburg, KY. To find more information about Breckinridge Memorial Hospital, please visit www.breckhealth.org
Sebo Tek Hearing Systems is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.